Francesca Musumeci

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 25

Top Topics

Tyrosine Kinase

Arabidopsis Thaliana

Chronic Myeloid Leukemia

Top Venues

International journal of molecular sciences

Pharmaceuticals (Basel, Switzerland)

Molecules (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Ilaria Giacchello, Annarita Cianciusi, Chiara Bertagnin, Anna Bonomini, Valeria Francesconi, Mattia Mori, Anna Carbone, Francesca Musumeci, Arianna Loregian, Silvia Schenone
Exploring a New Generation of Pyrimidine and Pyridine Derivatives as Anti-Influenza Agents Targeting the Polymerase PA-PB1 Subunits Interaction. Pharmaceutics 16 (7) (2024)
Davide Frumento, Giancarlo Grossi, Marta Falesiedi, Francesca Musumeci, Anna Carbone, Silvia Schenone
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment. International journal of molecular sciences 25 (3) (2024)
Ilaria Giacchello, Annarita Cianciusi, Chiara Bertagnin, Anna Bonomini, Valeria Francesconi, Mattia Mori, Anna Carbone, Francesca Musumeci, Arianna Loregian, Silvia Schenone
Exploring a New Generation of Pyrimidine and Pyridine Derivatives as Anti-Influenza Agents Targeting the Polymerase PA-PB1 Subunits Interaction. Pharmaceutics 16 (7) (2024)
Ilaria Giacchello, Annarita Cianciusi, Chiara Bertagnin, Anna Bonomini, Valeria Francesconi, Mattia Mori, Anna Carbone, Francesca Musumeci, Arianna Loregian, Silvia Schenone
Exploring a New Generation of Pyrimidine and Pyridine Derivatives as Anti-Influenza Agents Targeting the Polymerase PA-PB1 Subunits Interaction. Pharmaceutics 16 (7) (2024)
Davide Frumento, Giancarlo Grossi, Marta Falesiedi, Francesca Musumeci, Anna Carbone, Silvia Schenone
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment. International journal of molecular sciences 25 (3) (2024)
Davide Frumento, Giancarlo Grossi, Marta Falesiedi, Francesca Musumeci, Anna Carbone, Silvia Schenone
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment. International journal of molecular sciences 25 (3) (2024)
Naomi Scarano, Chiara Brullo, Francesca Musumeci, Enrico Millo, Santina Bruzzone, Silvia Schenone, Elena Cichero
Recent Advances in the Discovery of SIRT1/2 Inhibitors via Computational Methods: A Perspective. Pharmaceuticals (Basel, Switzerland) 17 (5) (2024)
Davide Frumento, Giancarlo Grossi, Marta Falesiedi, Francesca Musumeci, Anna Carbone, Silvia Schenone
Small Molecule Tyrosine Kinase Inhibitors (TKIs) for Glioblastoma Treatment. International journal of molecular sciences 25 (3) (2024)
Giancarlo Grossi, Naomi Scarano, Francesca Musumeci, Michele Tonelli, Evgeny Kanov, Anna Carbone, Paola Fossa, Raul R Gainetdinov, Elena Cichero, Silvia Schenone
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling. Molecules (Basel, Switzerland) 29 (8) (2024)
Francesca Musumeci, Silvia Schenone
Unlocking Potential and Limits of Kinase Inhibitors: The Highway to Enhanced Cancer Targeted Therapy. Pharmaceutics 16 (5) (2024)
Giancarlo Grossi, Naomi Scarano, Francesca Musumeci, Michele Tonelli, Evgeny Kanov, Anna Carbone, Paola Fossa, Raul R Gainetdinov, Elena Cichero, Silvia Schenone
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling. Molecules (Basel, Switzerland) 29 (8) (2024)
Giancarlo Grossi, Naomi Scarano, Francesca Musumeci, Michele Tonelli, Evgeny Kanov, Anna Carbone, Paola Fossa, Raul R Gainetdinov, Elena Cichero, Silvia Schenone
Discovery of a Novel Chemo-Type for TAAR1 Agonism via Molecular Modeling. Molecules (Basel, Switzerland) 29 (8) (2024)
Naomi Scarano, Chiara Brullo, Francesca Musumeci, Enrico Millo, Santina Bruzzone, Silvia Schenone, Elena Cichero
Recent Advances in the Discovery of SIRT1/2 Inhibitors via Computational Methods: A Perspective. Pharmaceuticals (Basel, Switzerland) 17 (5) (2024)
Francesca Musumeci, Silvia Schenone
Unlocking Potential and Limits of Kinase Inhibitors: The Highway to Enhanced Cancer Targeted Therapy. Pharmaceutics 16 (5) (2024)
Federica Poggialini, Chiara Vagaggini, Annalaura Brai, Claudia Pasqualini, Emmanuele Crespan, Giovanni Maga, Cecilia Perini, Noemi Cabella, Lorenzo Botta, Francesca Musumeci, Maria Frosini, Silvia Schenone, Elena Dreassi
Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4- d ]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme. Pharmaceutics 15 (2) (2023)
Federica Poggialini, Chiara Vagaggini, Annalaura Brai, Claudia Pasqualini, Emmanuele Crespan, Giovanni Maga, Cecilia Perini, Noemi Cabella, Lorenzo Botta, Francesca Musumeci, Maria Frosini, Silvia Schenone, Elena Dreassi
Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4- d ]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme. Pharmaceutics 15 (2) (2023)
Naomi Scarano, Francesco Di Palma, Nicola Origlia, Francesca Musumeci, Silvia Schenone, Sonia Spinelli, Mario Passalacqua, Elena Zocchi, Laura Sturla, Elena Cichero, Andrea Cavalli
New Insights into the LANCL2- ABA Binding Mode towards the Evaluation of New LANCL Agonists. Pharmaceutics 15 (12) (2023)
Federica Poggialini, Chiara Vagaggini, Annalaura Brai, Claudia Pasqualini, Anna Carbone, Francesca Musumeci, Silvia Schenone, Elena Dreassi
Sweet Cherry Extract as Permeation Enhancer of Tyrosine Kinase Inhibitors: A Promising Prospective for Future Oral Anticancer Therapies. Pharmaceuticals (Basel, Switzerland) 16 (11) (2023)
Federica Poggialini, Chiara Vagaggini, Annalaura Brai, Claudia Pasqualini, Emmanuele Crespan, Giovanni Maga, Cecilia Perini, Noemi Cabella, Lorenzo Botta, Francesca Musumeci, Maria Frosini, Silvia Schenone, Elena Dreassi
Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4- d ]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme. Pharmaceutics 15 (2) (2023)
Claudia Contadini, Claudia Cirotti, Anna Carbone, Mehrdad Norouzi, Annarita Cianciusi, Emmanuele Crespan, Cecilia Perini, Giovanni Maga, Daniela Barilà, Francesca Musumeci, Silvia Schenone
Identification and Biological Characterization of the Pyrazolo[3,4- d ]pyrimidine Derivative SI388 Active as Src Inhibitor. Pharmaceuticals (Basel, Switzerland) 16 (7) (2023)
Naomi Scarano, Francesco Di Palma, Nicola Origlia, Francesca Musumeci, Silvia Schenone, Sonia Spinelli, Mario Passalacqua, Elena Zocchi, Laura Sturla, Elena Cichero, Andrea Cavalli
New Insights into the LANCL2- ABA Binding Mode towards the Evaluation of New LANCL Agonists. Pharmaceutics 15 (12) (2023)
Naomi Scarano, Elena Abbotto, Francesca Musumeci, Annalisa Salis, Chiara Brullo, Paola Fossa, Silvia Schenone, Santina Bruzzone, Elena Cichero
Virtual Screening Combined with Enzymatic Assays to Guide the Discovery of Novel SIRT2 Inhibitors. International journal of molecular sciences 24 (11) (2023)
Federica Poggialini, Chiara Vagaggini, Annalaura Brai, Claudia Pasqualini, Emmanuele Crespan, Giovanni Maga, Cecilia Perini, Noemi Cabella, Lorenzo Botta, Francesca Musumeci, Maria Frosini, Silvia Schenone, Elena Dreassi
Biological Evaluation and In Vitro Characterization of ADME Profile of In-House Pyrazolo[3,4- d ]pyrimidines as Dual Tyrosine Kinase Inhibitors Active against Glioblastoma Multiforme. Pharmaceutics 15 (2) (2023)
Lorenzo Monteleone, Barbara Marengo, Francesca Musumeci, Giancarlo Grossi, Anna Carbone, Giulia Elda Valenti, Cinzia Domenicotti, Silvia Schenone
Anti-Survival Effect of SI306 and Its Derivatives on Human Glioblastoma Cells. Pharmaceutics 14 (7) (2022)
Francesca Musumeci, Annarita Cianciusi, Ilaria D'Agostino, Giancarlo Grossi, Anna Carbone, Silvia Schenone
Synthetic Heterocyclic Derivatives as Kinase Inhibitors Tested for the Treatment of Neuroblastoma. Molecules (Basel, Switzerland) 26 (23) (2021)